Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 315

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)

Open access
Buhl, Roland, Maltais, François, Abrahams, Roger, Bjermer, Leif, Derom, Eric, Ferguson, Gary, Fležar, Matjaž, Hébert, Jacques, McGarvey, Lorcan, Pizzichini, Emilio, Reid, Jim, Veale, Antony, Grönke, Lars, Hamilton, Alan, Korducki, Lawrence, Tetzlaff, Kay, Waitere-Wijker, Stella, Watz, Henrik, Bateman, Eric · 2015 · European Respiratory Journal

Abstract

Efficacy and safety of tiotropium+olodaterol fixed-dose combination (FDC) compared with the mono-components was evaluated in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in two replicate, randomised, double-blind, parallel-group, multicentre, phase III trials. Patients received tiotropium+olodaterol FDC 2.5/5 μg or 5/5 μg, tiotropium 2.5 μg or 5 μg, or olodaterol 5 μg delivered once-daily via Respimat inhaler over 52 weeks. Primary end points were forced expiratory volume in 1 s (FEV1) area under the curve from 0 to 3 h (AUC0–3) response, trough FEV1 response and St George's Respiratory Questionnaire (SGRQ) total score at 24 weeks. In total, 5162 patients (2624 in Study 1237.5 and 2538 in Study 1237.6) received treatment. Both FDCs significantly improved FEV1 AUC0–3 and trough FEV1 response versus the mono-components in both studies. Statistically significant improvements in SGRQ total score versus the mono-components were only seen for tiotropium+olodaterol FDC 5/5 μg. Incidence of adverse events was comparable between the FDCs and the mono-components. These studies demonstrated significant improvements in lung function and health-related quality of life with once-daily tiotropium+olodaterol FDC versus mono-components over 1 year in patients with moderate to very severe COPD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/09031936.00136014

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 315

Metadata

Authors
Buhl, R., Maltais, F., Abrahams, R., Bjermer, L., Derom, E., Ferguson, G., Fležar, M., Hébert, J., McGarvey, L., Pizzichini, E., Reid, J., Veale, A., Grönke, L., Hamilton, A., Korducki, L., Tetzlaff, K., Waitere-Wijker, S., Watz, H., & Bateman, E.
Venue
European Respiratory Journal
Published
2015-01-08
Volume
45
Issue
4
Pages
969-979
ISSN
  • 0903-1936 (ISSN-L)
  • 1399-3003
OpenAlex
W2128643475
Cited by
315
References
15
FWCI
43.53
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). https://app.cochat.ai/papers/10.1183/09031936.00136014
The paper
Buhl, R., Maltais, F., Abrahams, R., Bjermer, L., Derom, E., Ferguson, G., Fležar, M., Hébert, J., McGarvey, L., Pizzichini, E., Reid, J., Veale, A., Grönke, L., Hamilton, A., Korducki, L., Tetzlaff, K., Waitere-Wijker, S., Watz, H., & Bateman, E. (2015). Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). European Respiratory Journal. https://doi.org/10.1183/09031936.00136014

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.